Pre-earnings options volume in I MAB (ADS) is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 11.8%, or 61c, after results are released. Median move over the past eight quarters is 2.3%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
- I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
- 3 Penny Stocks to Watch Now, 8/5/25
- I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline
- Everest Medicines announces strategic equity investment in I-Mab